Other substances

[5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyfuran-2-yl](sodiylium)methyl [({[5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyfuran-2-yl]methoxy}(sodiooxo)phosphoryl)oxy]phosphonate

A nucleoside analogue.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
1
 Clinical trials

General information

[5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyfuran-2-yl](sodiylium)methyl [({[5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyfuran-2-yl]methoxy}(sodiooxo)phosphoryl)oxy]phosphonate is a nucleoside analogue similar to nadide (Singh et al., 2020).

Synonyms

NA1

 

Structure image - [5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyfuran-2-yl](sodiylium)methyl [({[5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyfuran-2-yl]methoxy}(sodiooxo)phosphoryl)oxy]phosphonate

NC(=O)C1=CN(C=CC1)[C@H]5O[C@@H](CO[P]([O-])(=O)O[P]([O-])(=O)OC[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)[N]3C=NC4=C(N)N=CN=C34)[C@H](O)[C@@H]5O

Supporting references

Link Tested on Impact factor Notes Publication date
Identification of FDA approved drugs and nucleoside analogues as potential SARS-CoV-2 A1pp domain inhibitor: An in silico study
nsp3 Small molecule In silico 		in silico 3.43

Predicted to inhibit the SARS-CoV-2 ADP-Ribose phosphatase nsp3.

 Dec/19/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT05230953 Fourth COVID-19 Vaccine Dose- mRNA1273 Active, not recruiting Phase 3 Jan/05/2022 Jul/04/2022
  • Alternative id - 9035-21
  • Interventions - Biological: mRNA1273 vaccine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Sheba Medical Center, Ramat-Gan, Israel
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 1000
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Geometric mean of antibody titers of each arm, on each time point|Solicited and unsolicited adverse events|Commulative incidents of infections in each arm
Export (.csv)